Cardiovascular 1
Primary imaging modality to evaluate aortic stenosis
TTE
Class of calcium channel blockers to avoid in HF
Nondihydropyridine
Initial nondrug therapy of acute SVT
Vagal maneuvers
BP target for prevention of symptomatic HF
<130/80 mm Hg
Indications for ABI measurement
Exertional leg symptoms, nonhealing leg ulcers, atypical leg symptoms
Holosystolic murmur along left sternal border that increases with inspiration
Tricuspid regurgitation
Loop diuretic with increased bioavailability and longer half-life
Torsemide or bumetanide
Treatment of symptomatic bradycardia without reversible cause
Permanent pacemaker
AHA/ACC guideline treatment for cholesterol for secondary prevention of ASCVD in patients aged ≤75 years
High-intensity statin therapy
Preferred hypertension drugs for pregnant patients
Labetalol and methyldopa
Valve abnormality associated with aortic coarctation
Bicuspid aortic valve
Typical murmur of HCM
Systolic murmur that increases with Valsalva and standing
Drugs to inhibit SVT induction and block AV conduction
β-Blockers and nondihydropyridine calcium channel blockers
Indications for aldosterone antagonist after STEMI
LVEF ≤40% and either HF symptoms or diabetes
Large groin hematoma or new bruit after femoral artery access for cardiac catheterization
Pseudoaneurysm
Classic radiographic findings of aortic coarctation
Rib notching and the “figure 3” sign (dilatation of aorta above and below area of coarctation)
Concentric ventricular wall thickness with low QRS voltage
Cardiac amyloidosis
Definitive treatment of atrial flutter
Catheter ablation
Diagnostic test for CAD when LBBB is present
Vasodilator stress myocardial perfusion imaging
Hypotension, back pain, and drop in hemoglobin level after femoral artery access for cardiac catheterization
Retroperitoneal hemorrhage
Most common structural disorder following TOF repair
Pulmonary regurgitation
Treatment to prevent SCD in high-risk patients with HCM
ICD
Imaging test for suspected arrhythmogenic RV cardiomyopathy/dysplasia
CMR imaging
Criteria for adding to maximal statin therapy in secondary ASCVD prevention in patients at very high risk
LDL cholesterol level ≥55 mg/dL or <50% reduction in LDL
The “6 P's” of acute limb ischemia
Paresthesia, pain, pallor, pulselessness, poikilothermia (coolness), paralysis